Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study-Reference-Cited by-同舟云学术

Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study

Published:2022-04 Issue: Volume:62 Page:135-143
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Cardoso Borges Fábio,Alves da Costa Filipa,Ramos Adriana,Ramos Catarina,Bernardo Catarina,Brito Cláudia,Mayer-da-Silva Alexandra,Furtado Cláudia,Ferreira Arlindo R.,Martins-Branco Diogo,Miranda Ana,Lourenço António

Funder

AstraZeneca

Janssen Pharmaceuticals

Angelini Pharma

Pfizer

Merck Sharp and Dohme

Novartis

Ipsen

Roche

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference36 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. International Agency for Research on Cancer. Breast cancer, GLOBOCAN 2020. Glob Cancer Obs n.d.

3. Registo Oncológico Nacional de todos os tumores na população residente em Portugal;Registo Oncológico Nacional,2018

4. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study;Walters;Br J Cancer,2013

5. Global analysis of advanced/metastatic breast cancer: decade report (2005-2015);Cardoso;Breast,2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials;Oncology and Therapy;2024-08-02

2. Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer;Breast Cancer Research and Treatment;2024-04-16

3. Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort;Clinical and Translational Oncology;2024-03-22

4. Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution;Journal of Pharmaceutical Policy and Practice;2024-01-17

5. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study;2024